Allergy Drug Pipeline and R&D 2009

Table of Contents

Executive Summary

1. Overview of the Global Allergy Medications Market

• 1.1 Allergies as a Medical Condition
  • 1.1.1 Types of Allergies
  • 1.1.2 Signs and Symptoms
  • 1.1.3 Physiological Response
    • Table 1-1. Gell & Coombs Classification of Allergic Reactions
  • 1.1.4 Prevalence
    • Table 1-2. Global Prevalence of Allergies
• 1.2 Medical Treatment of Allergies
  • 1.2.1 Prescription Medications: Current Usage & Unmet Needs
    • Table 1-3. Leading Prescription Allergy Medications
    • 1.2.1.1 U.S.
      • Table 1-4. U.S. DTC Advertising for Leading Rx and OTC Allergy Medications 2008
    • 1.2.1.2 Europe
    • 1.2.1.3 Japan
    • 1.2.1.4 ROW
  • 1.2.2 Non-Prescription Products: Current Usage & Unmet Needs
    • Table 1-5. Leading OTC Allergy Medications
  • 1.2.2.1 U.S.
  • 1.2.2.2 Europe
  • 1.2.2.3 Japan
  • 1.2.2.4 ROW

2. Global Allergy Medications Market Forecast 2008 - 2013

• 2.1 Rx Allergy Medications Market
  • 2.1.1 Rx Allergy Drug Market Forecast by Product
    • 2.1.1.1 Growth Drivers
      • Table 2-1. Rx Allergy Drug Market Forecast 2008 - 2013 by Product in $Million
    • 2.1.1.2 Market Restraints
      • Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
  • 2.1.2 Rx Allergy Drug Market Forecast by Region
    • Table 2-3. Rx Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
  • 2.1.3 Rx Allergy Drug Market Forecast by Product Class
    • Table 2-4. Rx Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
    • Table 2-5. Rx Allergy Drug Market Product Segments Share, 2008 vs. 2013
  • Figure 2-1. Rx Allergy Drug Market Product Segments Share, 2008
  • Figure 2-2. Rx Allergy Drug Market Product Segments Share, 2013
• 2.2 OTC Allergy Drug Market
  • 2.2.1 OTC Allergy Drug Market Forecast by Product
    • Table 2-6. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product in $Million
  • 2.2.2 Growth Drivers
  • 2.2.3 Market Restraints
  • 2.2.4 OTC Allergy Drug Market Forecast by Region
    • Table 2-7. OTC Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
  • 2.2.5 OTC Allergy Drug Market Forecast by Product Class
    • Table 2-8. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
• 2.3 Rx & OTC Allergy Drug Market
  • 2.3.1 Rx & OTC Allergy Drug Market Forecast by Leading Manufacturers
    • Table 2-9. RX & OTC Allergy Drug* Sales of Leading Manufacturers, 2008 - 2013 in $Million
  • 2.3.2 Rx & OTC Allergy Drug Market Share of Leading Drug Manufacturers
    • Table 2-10. Rx & OTC Market Shares of Leading Allergy Drug Manufacturers, 2008 vs. 2013
  • Figure 2-3. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2008
  • Figure 2-4. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2013

3. Allergy Drug Development: New Molecular Entities

• Table 3-1. Key Characteristics of NMEs, Generics and Indication Expansions
• 3.1 All Allergy Drug Developers Position
  • 3.1.1 Challenges in Allergy Drug Development
    • Table 3-2. All Allergy Drug Developers Product Position Overview
• 3.2 Key Products Under Development
  • Figure 3-1. Allergy Compounds Tested by Phase of Development
  • 3.2.1 Antihistamines
    • 3.2.1.1 Physiology and Mechanism of Action
    • 3.2.1.2 Leading Antihistamine Allergy Drug Candidates
      • Table 3-3. Antihistamine Developers Product Position
  • 3.2.2 Corticosteroids
    • 3.2.2.1 Physiology and Mechanism of Action
    • 3.2.2.2 Leading Corticosteroid Allergy Drug Candidates
      • Table 3-4. Corticosteroid Developers Product Position
  • 3.2.3 Mast Cell Inhibitors
    • 3.2.3.1 Physiology and Mechanism of Action
      • Figure 3-2. The Role of Mast Cells in Allergy Response
    • 3.2.3.2 Leading Mast Cell Inhibitor Allergy Drug Candidates
      • Table 3-5. Mast Cell Inhibitors Developers Product Position
  • 3.2.4 Allergy Immunotherapy
    • 3.2.4.1 Physiology and Mechanism of Action
    • 3.2.4.2 Leading Immunotherapy Allergy Drug Candidates
      • Table 3-6. Immunotherapy Developers Product Position
  • 3.2.5 Vaccines
    • 3.2.5.1 Physiology and Mechanism of Action
      • Figure 3-3. Production of TH2 Cytokines
    • 3.2.5.2 Leading Allergy Vaccine Candidates
      • Table 3-7. Vaccine Developers Product Position
  • 3.2.6 Other Types of Allergy Drugs
    • 3.2.6.1 Physiology and Mechanism of Action
    • 3.2.6.2 Other Leading Allergy Candidates
      • Table 3-8. Other Allergy Drug Developers Product Position
• 3.3 Global Market Forecast for New Allergy Drugs, 2008 - 2013
  • 3.3.1 New Allergy Drug Market Forecast: Total and Segment Market
    • Table 3-9. Sales of New Allergy Drugs by Segment, 2008 - 2013
    • Figure 3-4. Market Shares of New Allergy Drugs by Segment, 2013
  • 3.3.2 Growth Drivers
    • 3.3.2.1 The Importance of Patents
  • 3.3.3 Market Restraints

4. Allergy Drug Development: Indication Expansion

• 4.1 Indication Expansion for New Usage
  • Table 4-1. Selected Recent Allergy Drug Indication Expansions, U.S.
  • 4.1.1 The Economic Benefits of Indication Expansion
    • Table 4-2. U.S. R&D Expenditure for New Medicines by the Pharma-Industry
  • 4.1.2 Challenges in Allergy Drug Indication Expansion
    • Figure 4-1. Cost and Time Savings of Indication Expansions
• 4.2 Key Products Under Development
  • 4.2.1 Database of Allergy Indication Expansion Initiatives by Company
    • Table 4-3. Selected Allergy Drug Indication Expansion Trials
  • 4.2.2 Leading Areas of R&D Activity
    • 4.2.2.1 Clarinex
    • 4.2.2.2 Nasonex
    • 4.2.2.3 Patanase
    • 4.2.2.4 Singulair
    • 4.2.2.5 Veramyst
    • 4.2.2.6 Xolair
    • 4.2.2.7 Xyzal
• 4.3 Global Market Forecast for Allergy Drug Indication Expansions
  • Table 4-4. Sales of Allergy Drug Indication Expansions, 2008 - 2013 in $ Million
  • Table 4-5. Product Market Share of Allergy Drug Indication Expansions, 2009 vs. 2013
  • Figure 4-2. Product Market Share of Allergy Drug Indication Expansions, 2009
  • Figure 4-3. Product Market Share of Allergy Drug Indication Expansions, 2013
  • 4.3.1 Growth Drivers
  • 4.3.2 Market Restraints

5. Allergy Drug Development: Basic Research

• 5.1 Basic Research Group & Activity
  • Table 5-1. Leading Organizations & Details for Basic Allergy Research
  • 5.1.1 Challenges in Basic Allergy Research
    • Figure 5-1. National Institutes of Health Research Budget by Disease Area, Fiscal 2008
• 5.2 Key Areas of Investigation
  • Table 5-2. Recent Basic Research in the Field of Allergies
• 5.3 Unanswered Questions

6. Strategic Alliances for Allergy Drug Development

• 6.1 Types of Strategic Alliances
  • Figure 6-1. Comparison of Selected Deal Types
• 6.2 Current Strategic Alliances for Allergy Drug Development
  • Table 6-1. Ongoing Strategic Alliances for Allergy Drug Development

7. Activities of the Leading Allergy Drug Developers Common Research Item:

• 1) Table: Product Profile:
• 2) R&D Strength and Capabilities
• 3) Marketed Allergy Drugs
• 4) Allergy Drug Pipeline
• 5) Table: Profile

• 7.1 Alcon Research
• 7.2 Allergy Therapeutics
• 7.3 AstraZeneca
• 7.4 GlaxoSmithKline
• 7.5 Johnson & Johnson
• 7.6 Meda AB
• 7.7 Merck
• 7.8 Novartis
• 7.9 Sanofi-Aventis
• 7.10 Schering-Plough
• 7.11 Sepracor
• 7.12 UCB Pharma

8. Total Allergy Drug Market: Forecasts & Directions

• Table 8-1. Total Allergy Drug Sales by Segment, 2008 - 2013 in $Million
• Figure 8-1. Total Allergy Drug Sales Growth by Segment, 2008 - 2013
• Figure 8-2. Allergy Drug Market Share by Segment, 2008
• Figure 8-3. Allergy Drug Market Share by Segment, 2013

9. Other Top Companies with Allergy Projects

• Table 9-1. Other Top Companies with Late Stage Allergy Projects
• Table 9-2. Other Top Companies with Early Stage Allergy Projects

10. Database of Allergy Drug Developers